Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Ocugenix

Ownership
Private
Therapeutic Areas
Ophthalmology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules

Ocugenix General Information

Ocugenix develops small molecule therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. Their lead compound, Ocu‑110, aims to regress pathological blood vessels and fibrosis. The company’s approach offers hope for restoring lost sight by resolving aberrant wound responses in retinal disease. No published clinical results are available yet.

Contact Information

Website
https://pmc.ncbi.nlm.nih.gov/articles/PMC11756608/
Primary Industry
Biotech
Corporate Office
Pittsburgh, Pennsylvania
United States

Drug Pipeline

OCU-10-C-110
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Ocugenix's pipeline data

Book a demo

Key Partnerships

Innovation Works (investor/partner)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Ocugenix Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Ocugenix's complete valuation and funding history, request access »

Ocugenix Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals